WASHINGTON (dpa-AFX) - ViroPharma Inc. (VPHM) Thursday said it expects full-year 2012 worldwide net product sales to be in a range of $600 million to $660 million.
Analysts on a consensus expects revenues of $593.24 million for the full year.
The company expects net U.S. Cinryze sales to be $310 million to $330 million, while net Vancocin sales are expected to be $260 million to $310 million.
ViroPharma expects research and development, and selling, general and administrative expenses to be in a range of $230 million to $260 million.
Chief Executive Vincent Milano said, 'Whether measured by the continued progress and growth we demonstrated with our marketed life-saving therapies, or by the advancements we've made towards bringing additional solutions to patients suffering from severe unmet medical needs, the positive momentum generated throughout the period was palpable. We believe that the work we did in 2011 laid the foundation for continued strong financial growth in 2012, as evidenced by the guidance we are providing today.'
Copyright RTT News/dpa-AFX
© 2012 AFX News
